Effects of sintilimab combined with modified DCF regimen on tumor markers and expression of miR-133a-3p and miR-4317 in patients with advanced gastric cancer
Objective To explore the effects of sintilimab combined with modified DCF regimen on tumor markers and expression of miR-133a-3p and miR-4317 in patients with advanced gastric cancer.Methods A total of 80 patients with advanced gastric cancer received in our hospital from March 2019 to October 2022 were selected as the research objects.According to different treatment schemes,the patients were divided into control group and observation group,with 40 cases in each group.The control group was treated with modified DCF regimen,and the observation group was treated with sintilimab combined with modified DCF regimen.The levels of tumor markers,clinical efficacy and the expression of miR-133a-3p and miR-4317 were compared between the two groups.Results After treatment,the levels of carcino embryonic antigen(CEA),carbohydrate antigen 724(CA724)and carbohydrate antigen 199(CA199)in the observation group were lower than those in the control group(P<0.05).The complete remission(CR)rate,objective response rate(ORR)and disease control rate(DCR)in the observation group were higher than those in the control group,and the progressive disease(PD)rate was lower than that in the control group(P<0.05).At one week after treatment,the expression levels of miR-133a-3p and miR-4317 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The sintilimab combined with modified DCF regimen in the treatment of patients with advanced gastric cancer has a significant effect,it can effectively reduce the levels of tumor markers and up-regulate the expression of miR-133a-3p and miR-4317.
NETL
NSTL
万方数据
